VERU INC. Logo

VERU INC.

Biopharma firm developing drugs for cardiometabolic and inflammatory diseases.

VERU | US

Overview

Corporate Details

ISIN(s):
US92536C1036
LEI:
Country:
United States of America
Address:
2916 N. MIAMI AVENUE, 33127 MIAMI
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Veru Inc. is a late clinical-stage biopharmaceutical company dedicated to developing and commercializing novel treatments for cardiometabolic and inflammatory diseases. The company's pipeline is primarily focused on enobosarm, an oral selective androgen receptor modulator (SARM) designed to preserve muscle in patients undergoing weight loss therapy with GLP-1 drugs, thereby promoting higher-quality weight loss. Veru is also advancing sabizabulin, a novel oral anti-inflammatory agent for the treatment of atherosclerotic coronary artery disease. In addition to its cardiometabolic focus, the company has also developed therapies for oncology and viral-induced acute respiratory distress syndrome (ARDS).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all VERU INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for VERU INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for VERU INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Poltreg S.A. Logo
Pioneering T-regulatory cell therapies for autoimmune diseases like diabetes, MS, and ALS.
Poland
PTG
PolyPeptide Group AG Logo
A global CDMO specializing in peptide and oligonucleotide APIs for pharma and biotech partners.
Switzerland
PPGN
PolyPid Ltd. Logo
Develops localized, prolonged-release drug therapies for surgery, oncology & metabolic diseases.
United States of America
PYPD
Praxis Precision Medicines, Inc. Logo
Developing therapies for CNS disorders using insights from genetic epilepsies.
United States of America
PRAX
PRECIGEN, INC. Logo
Develops gene and cell therapies for difficult-to-treat diseases using precision technology.
United States of America
PGEN
Precipio, Inc. Logo
Provides blood cancer diagnostic services & products to improve accuracy for physicians & labs.
United States of America
PRPO
PRECISION BIOSCIENCES INC Logo
A clinical-stage company using ARCUS gene editing to treat cancer and rare genetic diseases.
United States of America
DTIL
Develops sensitive point-of-care biomarker diagnostics for human and animal health.
South Korea
335810
Prelude Therapeutics Inc Logo
Clinical-stage oncology company developing novel protein degraders and ADCs for cancer.
United States of America
PRLD
A global CDEMO offering end-to-end solutions for antibody therapeutics and biologics.
South Korea
334970

Talk to a Data Expert

Have a question? We'll get back to you promptly.